FY2018 EPS Estimates for Axovant Sciences Ltd (AXON) Lifted by Analyst

Axovant Sciences Ltd (NASDAQ:AXON) – Analysts at Oppenheimer upped their FY2018 EPS estimates for Axovant Sciences in a research note issued on Tuesday. Oppenheimer analyst J. Olson now anticipates that the biotechnology company will post earnings per share of ($2.30) for the year, up from their prior forecast of ($2.34). Oppenheimer has a “Hold” rating on the stock. Oppenheimer also issued estimates for Axovant Sciences’ Q4 2018 earnings at ($0.47) EPS, FY2019 earnings at ($1.59) EPS, FY2020 earnings at ($1.28) EPS, FY2021 earnings at ($1.04) EPS and FY2022 earnings at ($0.57) EPS.

Several other research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Axovant Sciences from a “buy” rating to a “hold” rating in a report on Wednesday. Cowen restated a “hold” rating on shares of Axovant Sciences in a report on Tuesday. ValuEngine upgraded shares of Axovant Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Chardan Capital upgraded shares of Axovant Sciences from a “sell” rating to a “neutral” rating and set a $2.50 target price for the company in a report on Wednesday, January 10th. Finally, Jefferies Group cut shares of Axovant Sciences from a “buy” rating to a “hold” rating and set a $6.00 target price for the company. in a report on Thursday, December 21st. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $13.61.

Shares of Axovant Sciences (NASDAQ AXON) traded down $0.18 on Thursday, reaching $1.63. 1,419,900 shares of the company traded hands, compared to its average volume of 2,165,688. Axovant Sciences has a fifty-two week low of $1.47 and a fifty-two week high of $27.98. The company has a quick ratio of 5.94, a current ratio of 4.58 and a debt-to-equity ratio of 0.45.

A number of hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN lifted its stake in Axovant Sciences by 1.6% in the second quarter. Wells Fargo & Company MN now owns 22,790 shares of the biotechnology company’s stock valued at $528,000 after acquiring an additional 355 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Axovant Sciences by 16.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,377 shares of the biotechnology company’s stock worth $519,000 after buying an additional 3,184 shares during the last quarter. California State Teachers Retirement System lifted its stake in shares of Axovant Sciences by 10.0% during the 2nd quarter. California State Teachers Retirement System now owns 52,949 shares of the biotechnology company’s stock worth $1,228,000 after buying an additional 4,800 shares during the last quarter. New York State Common Retirement Fund lifted its stake in shares of Axovant Sciences by 27.5% during the 2nd quarter. New York State Common Retirement Fund now owns 32,000 shares of the biotechnology company’s stock worth $742,000 after buying an additional 6,899 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in shares of Axovant Sciences by 24.7% during the 2nd quarter. Alliancebernstein L.P. now owns 52,000 shares of the biotechnology company’s stock worth $1,206,000 after buying an additional 10,300 shares during the last quarter. Hedge funds and other institutional investors own 96.82% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “FY2018 EPS Estimates for Axovant Sciences Ltd (AXON) Lifted by Analyst” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.themarketsdaily.com/2018/02/15/fy2018-eps-estimates-for-axovant-sciences-ltd-axon-lifted-by-analyst.html.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Earnings History and Estimates for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply